Welcome to our dedicated page for Microbot Medical news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Medical stock.
Microbot Medical, Inc. (NASDAQ: MBOT) is a pioneering pre-clinical medical device company focused on developing groundbreaking micro-robotic medical technologies. Established with the vision to transform minimally invasive surgeries—a fast-growing sector estimated to be close to $20 billion by 2015—Microbot Medical aims to provide cutting-edge micro-invasive technologies that assist physicians in targeting disease sites with unmatched precision. The company's innovative platforms, such as LIBERTY and the Self-Cleaning Shunt (SCS), are designed to improve surgical outcomes and the quality of life for millions of patients globally.
One of Microbot Medical's core technologies, the Virob platform, is an autonomous advancing micro-robot (AAMR) less than 1mm in diameter. This micro-robot can advance forward and backward autonomously, providing precise navigation through the body. Similarly, the LIBERTY Endovascular Robotic Surgical System aims to revolutionize endovascular procedures by eliminating the need for bulky and expensive equipment while reducing radiation exposure and physician strain.
Microbot Medical has been achieving significant milestones, including positive results from its pivotal GLP pre-clinical study and its recent Investigational Device Exemption (IDE) application to the FDA. These advancements pave the way for the company's first human clinical trials. Furthermore, the company has secured both domestic and global patents, fortifying its product portfolio and creating significant barriers to entry for competitors.
Microbot Medical is actively engaging in pre-commercial activities and strategic partnerships to ensure efficient commercialization channels for the LIBERTY system once it receives regulatory approval. The company is committed to advancing its technologies and aims to integrate future capabilities such as remote operations, imaging integration, and AI functionalities.
Despite challenges such as the COVID-19 pandemic and recent geopolitical events in Israel, Microbot Medical continues to meet its planned timelines and milestones. The company’s operations in Israel, the USA, and other parts of the globe remain uninterrupted, and it believes it will achieve regulatory and commercial milestones as scheduled.
For further information about Microbot Medical, please visit www.microbotmedical.com.
Microbot Medical Inc. (MBOT) has expanded its Scientific Advisory Board (SAB) by adding Dr. Francisco C. Carnevale, making a total of 13 Key Opinion Leaders globally. This strategic move enhances support for the regulatory and commercialization efforts of the LIBERTY® Robotic System. Dr. Carnevale, a notable vascular radiologist from Brazil, brings extensive expertise in Prostatic Artery Embolization. CEO Harel Gadot emphasized the importance of attracting global physicians to validate and advance the system’s clinical and economic advantages. The addition aims to broaden the technology's interventional applications and improve accessibility.
Microbot Medical Inc. (NASDAQ: MBOT) has announced the issuance of a new design patent for its LIBERTY® Robotic System's remote controller by the Japan Patent Office. This patent complements existing design patents in the U.S. and Europe, bolstering the company’s intellectual property portfolio. The LIBERTY system allows endovascular procedures to be performed remotely, which may reduce radiation exposure and physical strain for healthcare providers. Feedback from recent studies indicates that this innovative design enhances user experience, facilitating better patient care.
Microbot Medical (Nasdaq: MBOT) announced its upcoming webinar, “Access-Ability Live by MBOT,” scheduled for February 8, 2023, at 1:00 PM ET. Hosted by Dr. Eyal Morag, the event will feature Dr. Giora Weisz, a leading interventional cardiologist, discussing the evolving landscape of endovascular robotics and the role of robotic systems in cardiovascular procedures. This initiative aims to engage stakeholders in the field and highlight current innovations and challenges. The webinar is part of Microbot's ongoing effort to address key topics in healthcare and endovascular technologies.
Microbot Medical (NASDAQ: MBOT) announced a webinar titled Access-Ability Live by MBOT, scheduled for January 10, 2023. The event, moderated by Joe Mullings, will bring together experts from the medtech sector to discuss advancements in endovascular robotics and unmet medical needs. This series aims to facilitate discussions on critical topics in healthcare. Microbot focuses on developing pioneering micro-robotic technologies to improve patient outcomes. The firm’s approach includes a strong emphasis on innovation in endovascular procedures.
Microbot Medical (NASDAQ: MBOT) announced the upcoming webinar, "Access-Ability Live by MBOT," on December 21, 2022, at 1:00 PM ET. Dr. Eyal Morag will host Dr. Ripal Gandhi, an expert in endovascular robotics, who will discuss his experiences with robotic surgical procedures. The series aims to engage stakeholders in discussions on critical healthcare topics. Microbot is known for its innovative LIBERTY® Robotic System, focusing on micro-robotic technologies for medical applications. For more information, visit Microbot Medical.
Microbot Medical (Nasdaq: MBOT) has secured its third patent for the LIBERTY® Robotic System in Israel, bringing its total global patents for the system to ten. This patent enhances its intellectual property portfolio and is seen as a vital step towards regulatory approval and global commercialization. Chairman and CEO Harel Gadot emphasized the strategic importance of expanding the IP portfolio to maintain a competitive edge in key markets while progressing towards regulatory milestones and product release.
Microbot Medical has received a design patent allowance for its LIBERTY Robotic System remote controller from the USPTO, enhancing its global intellectual property portfolio. This controller was developed with input from physicians, focusing on improving user experience during endovascular procedures. The company will showcase the LIBERTY system at a healthcare conference in January 2023, allowing hands-on experience for interested parties.
Microbot Medical (NASDAQ: MBOT) is set to launch an educational webinar series titled “Access-Ability Live by MBOT”, aimed at creating a community of healthcare leaders focused on robotic technologies. The inaugural webinar, scheduled for November 16, 2022, at 1:00 pm ET, will feature discussions on the endovascular space and the LIBERTY® Robotic System. Hosted by Dr. Eyal Morag with guest speaker Dr. Sebastian Flacke, the series seeks to address pressing healthcare issues and share insights on emerging technologies.
Microbot Medical Inc. (Nasdaq: MBOT) has received a new patent allowance for its LIBERTY® Robotic System from the Israeli Patent Office, complementing a prior grant in the U.S. This patent covers the system's unique modular design, reinforcing its position as a leader in fully disposable robotic systems for endovascular procedures. CEO Harel Gadot highlighted the achievement of five patents for the system since its launch three years ago, emphasizing its potential to improve patient access to advanced treatments. The company is now entering regulatory phases and commercialization plans.
Microbot Medical (NASDAQ: MBOT) bolsters its Scientific Advisory Board (SAB) with the addition of Dr. Thierry Jacques De Baère, renowned head of the Interventional Radiology Unit at Institut Gustave Roussy in France. The SAB now includes 11 leading experts from the U.S., Europe, and Israel, enhancing support for the LIBERTY® Robotic System. This system, the first fully disposable robotic platform for endovascular procedures, aims to advance regulatory and commercialization goals. Dr. De Baère praises LIBERTY's reliability and ease of use, indicating strong potential for improving patient outcomes.
FAQ
What is the current stock price of Microbot Medical (MBOT)?
What is the market cap of Microbot Medical (MBOT)?
What is Microbot Medical, Inc.?
What is the LIBERTY Endovascular Robotic Surgical System?
What recent achievements has Microbot Medical accomplished?
What are the core technologies developed by Microbot Medical?
What is the vision of Microbot Medical?
How is Microbot Medical preparing for commercialization?
What impact do recent geopolitical events have on Microbot Medical's operations?
What is the Self-Cleaning Shunt (SCS) developed by Microbot Medical?
Who is acting as the exclusive placement agent for Microbot Medical's offering?
How can I get more information about Microbot Medical?
